





Scientific Program (Sultana Hall) Activity Type: Knowledge-based

	Opening Day (Day 1): Wednesday, September 11, 2024		
Time	Topic	Speaker	







19:00 – 20:00	Opening Remarks	
20:00 – 20:30	Opening Session: Conference Chair Speech	Prof. Ahmed Aljedai
	Dinner	
	Day 2: Thursday, September 12, 2024	
Time	Topic	Speaker
08:00 - 09:00	Conference Registration	
Session 1: Vi	ision in Action: Shaping Saudi Arabia's Healthcare Transformatio	on
Moderator: <u>D</u> 09:00 – 09:20	Pr. Hisham Badreldin Redefining Healthcare: National Healthcare Transformation in Sau Arabia Objectives: Review the key differences between national and global approaches healthcare transformation Discuss the role of various healthcare professionals (HCPs) beyond pharmacists in national and global healthcare transformation initiative Identify challenges and opportunities associated with integrating national and global healthcare strategies CE hour: 20 minutes	to Dr. Khalid Alshaibani
09:20 – 09:40	Adoption of Value-based Care Model at a National Level: Paving the way! Objectives: Discuss the importance and application of the EQ-5D-5L tool in health technology assessment Review disparities in healthcare access among public, private, and mixed sectors within the Kingdom of Saudi Arabia Review the privatization process in Saudi healthcare, its progression and its consequences on the quality and accessibility of patient care AUN # 0662-0000-24-001-L99-P CE hour: 20 minutes	Prof. Ahmed Aljedai
09:40 – 10:00	Addressing Healthcare Disparities in Different Regions in Saudi Arabia Objectives: Explain the density and geographical disparities of pharmacy practice in urban versus rural and small-city settings in Saudi Arabia Outline the challenges impacting the distribution and operation of pharmacy practice in rural areas of Saudi Arabia Discuss the methods employed in projecting and planning for the pharmacy workforce to meet regional healthcare needs Describe strategies to improve the distribution and quality of pharmacy practice in rural areas AUN# 0662-0000-24-003-L04-P CE hour: 20 minutes	Dr. Khaled Alabdulkareem
10:00 - 10:15	Panel Discussion	
10:15 – 10:25	Coffee Break	
	eading Health with Impact: Pharmacy Leadership in a Global Con	ntext
Moderator: D 10:25 – 10:45	The Role of International Pharmaceutical Federation (FIP) in Advancing Global Pharmacy Profession Objectives: Explain the importance of cross-border collaboration in pharmacy practice Identify key challenges and barriers to cross-border collaboration in pharmacy field, and explore effective strategies to overcome these challenges	Dr. Paul Sinclair







Tr.	Discussion of the second of th	
	Discuss successful examples of cross-border collaboration initiatives in pharmacy profession.	
	pharmacy profession AUN# 0662-0000-24-004-L99-P	
	CE hour: 20 minutes	
	Effective Leadership Competencies for Clinical Pharmacists	
	Objectives:	
10 / 10 L)	Define leadership in the context of clinical pharmacy practice and avalete its significance in driving innevetion and advancing healthcare.	
	explore its significance in driving innovation and advancing healthcare	
10:45 – 11:05	Identify key leadership competencies essential for clinical pharmacists	Prof. Jo Ellen Rodgers
10.45 - 11.05	Discuss strategies for developing and enhancing leadership skills within the clinical pharmacy workforce	Prof. 30 Eller Rougers
	Explain how leadership in clinical pharmacy can influence healthcare	
	policy, education, and practice standards regionally and globally	
	AUN# 0662-0000-24-005-L99-P	
	CE hour: 20 minutes	
	Empowering Population Health: Leadership in Advancing National	
	Population Health and Surveillance to the Global Level	
	Objectives:	
	Recognize the key components and strategies of national population	
	health initiatives and their impact on global health surveillance systems	
44.05 44.05	Discuss the effectiveness of leadership approaches in advancing	D. C. II.
11:05 – 11:25	population health initiatives from a national to a global scale	Dr. Suliman Alghnam
	Explain leadership principles to foster global collaboration and	
	innovation in local population health initiatives aimed at enhancing	
	national health outcomes	
	AUN# 0662-0000-24-006-L99-P	
	CE hour: 20 minutes	
11:25 – 11:40	Panel Discussion	SX.
11:40 – 13:00	Prayer and Lunch Break	
Special Panel	1: Healthcare Accessibility in the Kingdom of Saudi Arabia	
Moderator: D	r. Hala Joharji	
		Dr. Hadi Alenazy
		Dr. Shabab Alghamdi
13:00 – 13:50	Healthcare Accessibility in the Kingdom of Saudi Arabia	Prof. Awad Alomari
10.00 10.00	Healtheate Accessionity III the Kingdom of Saddi Alabia	Dr. Abdulrahman
		Alqahtani
		Dr. Wael Yar
13:50 – 14:00	Coffee Break	
	ture Frontiers: Revolutionizing Pharmacy Education and Clinical F	Research
Moderator: D	r. Omar Alshaya	
	Technical Standards for Advancing Pharmacy Education	
	Objectives:	
	Explain the role and importance of technical standards in enhancing the	
	quality and consistency of pharmacy education across different	
	institutions.	
	Identify and discuss key technical standards relevant to pharmacy	
14:00 – 14:20	education	Prof. Jo Ellen Rodgers
	Explain how technology can be integrated into pharmacy education to most technology standards such as a learning platforms, and digital	
	meet technical standards, such as e-learning platforms, and digital assessment tools.	
	Discuss common challenges faced by educational institutions in	
	implementing technical standards and propose best practices to	
	overcome these challenges.	
	AUN# 0662-0000-24-009-L99-P	
	CE hour: 20 minutes	
	Advancing Clinical Pharmacy through Research: Navigating Funds	
	Advancing Chinean Harmady through Research Navigating Fullus	
14:20 - 14:40		Prof Majed Alieraisy
14:20 – 14:40	and Grants Objectives:	Prof. Majed Aljeraisy







	Recognize the significance of clinical research in advancing evidence- based practice	
	Identify various sources of funding and grants to support clinical	
	pharmacy research projects	
	Discuss the importance of translation of funded clinical research into	
	clinical pharmacy practice to improve patient care and outcomes	
	AUN# 0662-0000-24-008-L99-P	
	CE hour: 20 minutes	
	Pathways to Excellence: Residency, Fellow, and Specialized	
	Professional Programs Objectives:	
	Identify the role of post-graduate training programs in preparing	
	pharmacists for advanced clinical practice	
	Discuss the difference between ASHP accreditation and SCFHS	
14:40 - 15:00	accreditation in terms of standards, processes, and international	Dr. Ahmed Aldemerdash
	recognition	
	Review the eligibility criteria and application process for residency, fellowship, and professional programs in clinical pharmacy	
	Discuss the impact of post-graduate training on career advancement	
	and specialization in pharmacy practice	
	AUN# 0662-0000-24-010-L99-P	
	CE hour: 20 minutes	
	Clinical Pharmacy Faculty Provision of Direct Patient Care,	
	Challenges, and Opportunities	
	Objectives:	
	Identify the role of clinical pharmacy faculty in providing direct patient	
15:00 – 15:20	care and interdisciplinary collaboration Discuss the challenges faced by clinical pharmacy faculty in delivering	Dr. Nora Alkhudair
10.00 10.20	direct patient care	Dr. 1101a / III. Iaaaii
	Describe opportunities for clinical pharmacy faculty to enhance and	
	promote patient care	
	AUN# 0662-0000-24-011-L99-P	
	CE hour: 20 minutes	
	Fostering Success: The Impact of Mentorship on Career	
	Development in Clinical Pharmacy	
	Objectives: Highlight the significance of mentorship in shaping professional growth	
45.00 45.40	of healthcare professionals	B
15:20 – 15:40	Identify key factors for the success of mentorship programs within the	Dr. Osama Tabbara
	pharmacy profession	
	Discuss models for implementing an effective mentorship program	
	AUN# 0662-0000-24-012-L99-P	
15:40 – 15:55	CE hour: 20 minutes Panel Discussion	
15:55 – 16:05	Coffee Break	
	nquering Infections: Challenges and Management in Infectious Dis	seases
	r. Thamer Almangour	
	New Treatment for Cytomegalovirus Infection	
	, g	
	Objectives:	
16:05 – 16:25	Review newer drugs for cytomegalovirus infection	Dr. Yazed Alsowaida
10.03 - 10.23	Discuss clinical trials evaluating new cytomegalovirus drugs Discuss clinical trials evaluating new cytomegalovirus drugs Discuss clinical trials Discuss clinical	
	Explain the place of therapy for newer cytomegalovirus drugs AUN# 0662-0000-24-013-L01-P	
	CE hour: 20 minutes	
	Self-Administered OPAT Challenges and Opportunities	
10:25 10:45	Objectives:	Dr. Doob Al-ll
16:25 – 16:45	Identify different outpatient parenteral antimicrobial therapy delivery	Dr. Bashayer Alshehail
	models	







Vi-		
	Describe the self-administered outpatient parenteral antimicrobial therapy (S-OPAT) program Review an existing program workflow by sharing the experience of a	
CTINE I	tertiary care hospital in Saudi Arabia	
	AUN# 0662-0000-24-014-L01-P CE hour: 20 minutes	
	Stenotrophomonas maltophilia: Challenges and Treatment Objectives: Review the current challenges in the treatment of stenotrophomonas	
	infection	
16:45 – 17:05	 Discuss the current treatment strategy for stenotrophomonas infection Explain evidence behind the use of novel antibiotics in MDR 	Dr. Sara Almuhisen
	Stenotrophomonas AUN# 0662-0000-24-015-L01-P	
	CE hour: 20 minutes	
	The Shorter It Is, The Better: Latest Updates of Therapy Duration in Common Infectious Diseases	
	Objectives:	
17:05 – 17:25	Review the latest updates for the duration of therapy for infectious diseases	Prof. Abdullah
17.05 - 17.25	Discuss the application for the duration of therapy for infectious diseases in pharmacy practice	Almohaizie
	AUN# 0662-0000-24-016-L01-P	
17:25 – 17:40	CE hour: 20 minutes Panel Discussion	
17.25 - 17.40	End of Day 2	
	Day 3: Friday, September 13, 2024	
Time	Topic	Speaker
	12: Managing Clinical Pharmacy Services Across Different Institution	
Moderator: D	r. Abdullah Alhammad	
08:30 – 09:20	Managing Clinical Pharmacy Services Across Different Institutions	Dr. Rayd Almehizia Dr. Mukhtar Alomar
		Dr. Hala Joharji Dr. Abdullah Alrajhi
09:20 - 09:30	Coffee Break	
	eyond Boundaries: Pioneering Precision and Innovation in Healthca ṛ. Hana Al Alshaykh	are
	Pharmaceutical Industry Ventures and Innovation: A Newer Leverage Objectives:	
	 Describe key strategies involved in managing ventures and innovation within pharmaceutical industry 	
09:30 - 09:50	Discuss the nature of operation and business management in	Prof. Amer Alanazi
33.53	pharmaceutical industry Describe a strategic plan for pharmaceutical industry venture that	
	incorporates innovative leverage techniques	
	AUN# 0662-0000-24-017-L99-P CE hour: 20 minutes	
	Advances in Pharmacogenomics: Shaping Personalized Patient Care	
	Objectives: Recognize the core principles of pharmacogenomics	
	Describe how pharmacogenomics is revolutionizing patient care by	
	enabling personalized treatment plans and enhancing outcomes	
09:50 – 10:10	Review the influence of existing and emerging pharmacogenomic data on clinical decision-making and the development of patient care	Dr. Cyrine-Eliana Haidar
	guidelines	
	 Discuss future trends in pharmacogenomics research and their potential implications for advancing personalized medicine in clinical settings 	
	AUN# 0662-0000-24-018-L99-P	
	CE hour: 20 minutes	







10:10 – 10:30	Biosimilars Unveiled: Understanding the Clinical Development Program Objectives: Describe the key stages and regulatory requirements in the clinical development of biosimilars Discuss the process of clinical development program and the pathway to regulatory approval for biosimilars Review the ethical issues and safety considerations essential to the development and clinical use of biosimilars AUN# 0662-0000-24-019-L99-P CE hour: 20 minutes	Dr. Ahmed AlKhaldi
10:30 – 10:50	SSCP and SHIP Position Statement on Artificial Intelligence Utilization and Data Governance in Healthcare Objectives: Identify key principles of the use of artificial intelligence (AI) and data governance in healthcare outlined by the Saudi Society of Clinical Pharmacy (SSCP) and Saudi Health Informatics and Privacy (SHIP) position statement Recognized specific impacts of AI and data governance on pharmacy practice in healthcare Identify ethical and legal considerations pharmacists must recognize when implementing AI technologies and data governance strategies in healthcare AUN# 0662-0000-24-020-L99-P CE hour: 20 minutes	Dr. Abdulrahman Alshaya
10:50 – 11:10	Artificial Intelligence and Vigilance: Using AI to Optimize Patient Safety Objectives: Explain how artificial intelligence (AI) is being integrated into clinical pharmacy to enhance patient safety and care Describe the advantages and obstacles of implementing AI technologies in pharmacy practice, including improved accuracy, efficiency, and patient outcomes Discuss strategies for effectively integrating AI technologies into clinical pharmacy to optimize patient care and service quality AUN# 0662-0000-24-021-L99-P CE hour: 20 minutes	Dr. Abdulgader Almoeen
11:10 – 11:30	Panel Discussion	
	Prayer and Lunch Break	
Session 6: B	iotech Horizons: Navigating Advancements in Biotechnology	
	r. Najwa AlGhamedi	
13:30 – 13:50	Role of Saudi Food and Drug Authority in Achieving National Biotechnology Strategy Objectives: Recognize the SFDA's regulatory framework in achieving national biotechnology strategy Identify the impact of SFDA's regulatory policies on the biotechnology sector development Discuss future insights and directions on developments in biotechnology AUN# 0662-0000-24-022-L99-P CE hour: 20 minutes	H.E. Prof. Hisham Aljadhey
13:50 – 14:10	The Role of Research Centers in Achieving National Biotechnology Strategy Objectives: Define the specific roles that research centers play in the development and expansion of the biotechnology field Examine the impact of research centers on biotechnology advancements Discuss the current initiatives and future directions in biotechnology being pursued by research centers AUN# 0662-0000-24-023-L99-P	Dr. Hisham Badreldin







	CE hour: 20 minutes	
	CE hour: 20 minutes	
14:10 – 14:30	Fostering the Public-private Partnership to Advance Biotechnology Objectives: Recognize different public-private partnership (PPP) models in the biotechnology sector Assess the advantages and obstacles of PPPs in biotechnological advancements Identify key strategies that contribute to successful PPPs in biotechnology AUN# 0662-0000-24-024-L99-P CE hour: 20 minutes	Dr. Abdelali Haoudi
14:30 – 14:50	Localized Innovation: Where We Stand in Biological and Gene Therapy Objectives: Describe the current status of biologics and gene therapy. Review recent advancements in biologics and gene therapy. Review the impact of localized innovations in biologics on the local market and patient care. Discuss the importance of collaboration between stakeholders in driving innovation and overcoming challenges. AUN# 0662-0000-24-025-L99-P CE hour: 20 minutes	Dr. Raed Al-Swayed
14:50 - 15:05	Panel Discussion	
15:05 – 15:15	Coffee Break	
	arnessing Formulary Management, Data and Resources for Smart r. Nada Alagil	er Healthcare
15:15 – 15:35	Medication Utilization Evaluation for Enhanced Patient Safety: The SFDA MUE Initiative Objectives: Explain medication utilization evaluation (MUE) and its role in patient safety Discuss the SFDA MUE National Study: key findings and insights Review MUE data for targeted interventions and continuous improvement AUN# 0662-0000-24-026-L99-P CE hour: 20 minutes	Dr. Solaiman Alhawas
15:35 – 15:55	Integrating Pharmacogenomics into Healthcare Medical Records and Hospital Protocols Objectives: Discuss the importance of integrating pharmacogenomics into hospital systems and protocols to improve patient outcomes. Discuss the necessary infrastructure within medical records systems and hospital protocols to incorporate pharmacogenomic information effectively. Explain standardized protocols for the use of pharmacogenomic data in clinical decision-making to ensure safe and effective patient care. Describe a continuous monitoring system to assess the impact of pharmacogenomics on healthcare outcomes. AUN# 0662-0000-24-027-L99-P CE hour: 20 minutes	Dr. Cyrine-Eliana Haidar
15:55 – 16:15	Building the Foundation: Drug Information Role in Designing Effective Data Collection System for Real-World Evidence Objectives: Recognize the importance of effective data collection sheets for real-world evidence (RWE) Discuss core principles for designing effective data collection sheets for real-world evidence (RWE) Review data collection sheets for specific real-world evidence (RWE) studies	Dr. Shatha Almuhaideb







	AUN# 0662-0000-24-028-L99-P CE hour: 20 minutes	
16:15 – 16:30	Panel Discussion	
	End of Day 3	
	Day 4: Saturday, September 14, 2024	
Time	Topic	Speaker
	aking Critical Care and Emergency Medicine Knowledge to the Nex	
	r. Abdulrahman Alshaya	20101
08:30 – 08:50	Current Trends and Breakthroughs in Emergency Medicine Objectives: Review recent advancements in emergency medicine literature Identify emergency medicine-related updates that enhance patient care, and improve clinical outcomes Review emerging trends in emergency medicine research AUN# 0662-0000-24-029-L99-P hour: 20 minutes	Dr. Allyson Wexler
08:50 – 09:10	Immunocompromised Patients in ICU: What to consider? Objectives: Identify key considerations and best practices for the management of immunocompromised patients in the intensive care unit (ICU) Discuss strategies for preventing and managing immunocompromised patients-related complications in the ICU Discuss the challenges associated with managing infections in immunocompromised patients admitted to the ICU. AUN# 0662-0000-24-030-L99-P CE hour: 20 minutes	Dr. Marwa Amer
09:10 – 09:30	 Impact of Plasma Exchange on ICU Medications Objectives: Explain the dynamic of plasma exchange machines used for certain cases in the intensive care unit (ICU) Discuss the impact of plasma exchange on the pharmacokinetics, dosing requirements, and therapeutic outcomes of medications commonly administered in the ICU setting, including antimicrobials and anticoagulants Discuss the implications of plasma exchange on drug monitoring and therapeutic drug monitoring practices in the ICU AUN# 0662-0000-24-031-L01-P CE hour: 20 minutes 	Dr. Raed Kensara
09:30 – 09:50	Simplified Approach for Managing Poisoned Patients Objectives: Identify key principles and guidelines for the initial assessment and management of poisoned patients in the emergency department Explain a systematic approach for the rapid identification of toxic substances and assessment of the poisoning severity based on clinical presentation, history and laboratory findings Describe simplified algorithms and decision-making tools for poisoned patient management AUN# 0662-0000-24-032-L01-P CE hour: 20 minutes	Dr. Ahmed Aljabri
09:50 - 10:05	Panel Discussion	
10:05 – 10:15		
	ne Pivotal Role of Ambulatory Care Pharmacy	1/4
	r. Rana Almohaimeed	
10:15 – 10:35	Heart Matters in Cancer Care: Updates and Management in Cardio-Oncology Objectives: Recognize principles of cardio-oncology in the management of cancer patients with cardiovascular complications	Prof. Jo Ellen Rodgers







	 Discuss the cardiotoxic effects of common oncological treatments and the mechanisms Review of the current strategies for monitoring heart health in cancer patients receiving cardiotoxic anticancer agents Explain practical approaches in the management of cardiac complications in oncology AUN# 0662-0000-24-033-L01-P 	
	CE hour: 20 minutes	
10:35 – 10:55	Expanding Pharmacist Role Towards Preventive Medicine in Public Health Objectives: Discuss the public health role in promoting public health Describe the role of pharmacists in public health planning and promotion Identify new opportunities for ambulatory care pharmacists' involvement in future public health initiatives Discuss examples of pharmacists' contributions to promoting public health AUN# 0662-0000-24-034-L99-P CE hour: 20 minutes	Dr. Bashayr Alsuwayni
	Effective Strategies to Establish an Ideal Ambulatory Care Clinic Objectives: Describe the principles and advantages of establishing an ambulatory care pharmacy clinic Recognize ambulatory care potentials and enhance patient outcomes Discuss a structured approach for developing an effective plan for an ambulatory care pharmacy clinic, encompassing key elements such as service offerings and regulatory compliance AUN# 0662-0000-24-035-L99-P CE hour: 20 minutes	Dr. Abdulaziz Alqahtani
	Panel Discussion	
Special Panel 3 Moderator: Dr.	3: Ambulatory Care Clinical Pharmacy: A Sustainable Service Aysha Bader	
11:25 – 12:15	Ambulatory Care Clinical Pharmacy: A Sustainable Service	Dr. Abubker Omaer Dr. Abdulaziz Alhossan Dr. Sarah Abutaily
12:15 – 13:30	Prayer and Lunch Break	
	End of Day 4	